What do brokers think of the ResMed (ASX:RMD) share price dip?

The ResMed Inc (ASX: RMD) share price took a dive last Friday on disappointing quarterly results. Could this be a buy the dip moment?

| More on:
Falling ASX share prices represented by girl falling asleep at her computer with her head in her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price continues to take a beating on Monday after releasing its third-quarter results last week. Its shares have lost almost 9% in the last two trading sessions. 

At the time of writing, the ResMed share price is down 5.24%, trading at $24.80.

Why is the ResMed share price under pressure?

The narrative for the ResMed share price is similar to that of Kogan.com Ltd (ASX: KGN), Redbubble Ltd (ASX: RBL) and Temple & Webster Group Ltd (ASX: TPW).

COVID-19 supercharged the demand for ResMed products such as ventilators, masks and circuits. As the global pandemic unwinds, companies are finding it challenging to surpass elevated earnings experienced in FY20. 

Brokers weigh in on the dip 

Citi: Undervalued but cautious 

ResMed continues to perform well operationally under a difficult environment, according to Citi. The broker believes that are many upsides for the business in a post-COVID world, including higher market growth with the return of its previous sleep apnea patients, market share gains with its new Airsense 11 device and increased penetration in the chronic obstructive pulmonary disease (COPD) market. 

Citi believes the RedMed share price is about 10% undervalued but cautiously downgraded its rating from buy to neutral. Its target priced also retreated from $29.00 to $28.50. 

Credit Suisse: Tough comparables but industry upside in FY22 

Credit Suisse describes the March quarter result as a disappointment at the revenue level, although the company is cycling a period of tough comparables. 

Looking ahead, the broker eyes ResMed's new CPAP device, AirSense 11, which is expected to be widely launched in the US by the end of 2021. The broker believes the industry will enter a resupply cycle in FY22 for devices, forecasting approximately 11% device growth in the US. 

Credit Suisse retained an outperform rating and slightly lowered its share price target from $29.50 to $29.00. 

Macquarie: Medium-term forecasts are unchanged 

The March quarter results were below Macquarie's expectations, but gradual recovery in new patient growth is anticipated across 2021-22. 

The broker remains positive in the medium-term, leaving forecasts unchanged. A neutral rating was retained, and the target price reduced from $28.00 to $27.50. 

Morgans: Current headwinds are more cyclical than structural 

Morgans described the current headwinds for the business as cyclical rather than structural. It believes an upgrade cycle is imminent, with its next-generation sleep apnea platform due for commercialisation by the end of the year. 

Looking at the third-quarter result, the broker felt the performance was mixed as underlying revenue growth was flat, gross margins were contracting on higher costs and an unfavourable product mix. However, profit was slightly ahead of expectations on lower opex,  improving patient flows and ongoing mask resupply. 

Morgans rated the ResMed share price as an add but lowered its target price from $30.09 to $29.14.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd and Temple & Webster Group Ltd. The Motley Fool Australia has recommended Kogan.com ltd, ResMed Inc., and Temple & Webster Group Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today

Why are these shares taking a tumble today? Let's find out.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Appen, DroneShield, Gentrack, and New Hope shares are dropping today

These shares are starting the week in the red. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Dexus, Dusk, Fletcher Building, and Paladin Energy shares are falling today

These shares are ending the week in the red. But why?

Read more »

Couple look at a bottle of wine while trying to decide what to buy.
Consumer Staples & Discretionary Shares

Treasury Wine shares: Buy, hold, or sell? Here's Macquarie's take

What is Macquarie forecasting for Treasury Wine shares amid the CEO’s unexpected exit?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Newmont, NRW, Peet, and Treasury Wine shares are dropping today

Let's find out why investors are selling down these shares on Thursday.

Read more »